Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.

医学 成纤维细胞生长因子受体 肿瘤科 内科学 成纤维细胞生长因子 受体
作者
Shubham Pant,Joon Oh Park,Wu‐Chou Su,Martin Schüler,Yohann Loriot,Gopa Iyer,Toshihiko Doi,Shukui Qin,Josep Tabernero,Hans Prenen,Gunnar Folprecht,Helen Winter,Graziela Zibetti Dal Molin,Hussein Sweiti,Saltanat Najmi,Constance Hammond,Huimin Liao,Shibu Thomas,Spyros Triantos,Yin‐Hsun Feng
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 4121-4121
标识
DOI:10.1200/jco.2024.42.16_suppl.4121
摘要

4121 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for the treatment of adult pts with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations whose disease has progressed on or after ≥1 line of prior systemic therapy. Primary analysis of the RAGNAR study demonstrated tumor agnostic efficacy in patients with solid tumors harboring susceptible FGFR mutations or fusions (1). Results from the LUC2001 study in patients with cholangiocarcinoma were previously presented (2). Here we report on the pooled analysis of patients with cholangiocarcinoma treated in the RAGNAR and LUC2001 studies. Methods: RAGNAR (NCT04083976) and LUC2001 (NCT02699606) enrolled patients with advanced solid tumors after ≥1 prior lines of therapy. RAGNAR patients had exhausted standard of care therapies; LUC2001 enrolled patients only in China, Taiwan, and South Korea. Patients received erdafitinib (8 mg daily, optional up-titration) until disease progression or toxicity. Patients with cholangiocarcinoma and predefined FGFR alterations were pooled into an analysis of efficacy (objective response rate by Independent Review Committee [IRC], duration of response, progression free survival, overall survival) and safety. Results: At data cutoff, 78 patients had received erdafitinib (RAGNAR: 66; LUC2001: 12). Median efficacy follow-up was 15 months. Median (range) age was 56 years (24;77); 60% female, 47% White, 39% Asian. Patients had a median of 2 prior lines of therapy; 92% patients had visceral metastases, and 17% of patients responded to prior therapy. 94% of patients had FGFR2 alterations, and 91% of patients had fusions. Objective response rate by IRC was 55%. Responses were observed in patients with both, fusions or mutations. Median time to onset of response was 1.7 month; median duration of response, progression free survival, and overall survival were 6.9 (95% CI: 4.37, 8.61), 8.5 (95% CI: 6.83, 9.72), and 18.1 (95% CI: 13.40, 24.28) months, respectively. Most common treatment-emergent adverse events (TEAEs) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), palmar-plantar erythrodysesthesia (51%); 42% of patients had serious TEAEs and 12% discontinued treatment due to an AE. No treatment-related deaths were observed. Conclusions: Data from pooled analysis of the RAGNAR and LUC2001 studies confirm robust efficacy of erdafitinib in a diverse population of patients with advanced or metastatic cholangiocarcinoma and prespecified FGFRfusions or mutations. Safety data were consistent with the erdafitinib safety profile. 1. Pant 2023. 2. Feng 2022. Clinical trial information: NCT04083976 and NCT02699606 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一一完成签到,获得积分10
刚刚
永沐华光完成签到,获得积分10
刚刚
圆圆完成签到,获得积分20
刚刚
刚刚
橙子完成签到,获得积分10
1秒前
年轻的钢笔完成签到 ,获得积分10
1秒前
1秒前
1秒前
1秒前
1秒前
脑洞疼的应助被善良安荷采纳,获得10
1秒前
老实大山完成签到,获得积分10
2秒前
2秒前
可爱的函函的应助被栗松琛采纳,获得10
2秒前
JamesPei的应助被陈123采纳,获得10
3秒前
Orange的应助被Ra采纳,获得10
4秒前
Xuan完成签到,获得积分0
4秒前
科研汪完成签到 ,获得积分20
4秒前
科研通AI6.2的应助被呃呃采纳,获得10
4秒前
archsaly完成签到,获得积分10
5秒前
小刘先生完成签到,获得积分10
5秒前
5秒前
5秒前
夏梓硕发布了新的文献求助10
5秒前
5秒前
6秒前
在水一方的应助被godgyw采纳,获得10
6秒前
HAO完成签到,获得积分10
6秒前
嘻嘻哈哈的应助被桌上有足球采纳,获得10
6秒前
6秒前
华仔的应助被lllll77采纳,获得10
6秒前
甲虫发布了新的文献求助10
6秒前
whj完成签到 ,获得积分10
6秒前
7秒前
7秒前
7秒前
复苏发布了新的文献求助10
7秒前
Samuel发布了新的文献求助30
7秒前
科研通AI6.2的应助被俏皮问筠采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153003
求助须知:如何正确求助?哪些是违规求助? 9549655
关于积分的说明 21694572
捐赠科研通 7741466
什么是DOI,文献DOI怎么找? 3425413
关于科研通互助平台的介绍 2550550
邀请新用户注册赠送积分活动 2468971